MRK 016 - CAS 783331-24-8
Catalog number: 783331-24-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H20N8O2
Molecular Weight:
368.40
COA:
Inquire
Targets:
GABA Receptor
Description:
MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid, ketamine-like antidepressant effects in animal models of depression.
Purity:
>98%
Appearance:
White solid
Synonyms:
MRK-016; MRK 016; MRK016; AC1OCFM5; GTPL4257;3-[3-tert-butyl-2-[(2-methyl-1,2,4-triazol-3-yl)methoxy]pyrazolo[1,5-d][1,2,4]triazin-7-yl]-5-methyl-1,2-oxazole
Solubility:
DMSO to 100 mM
ethanol to 10 mM
Storage:
-20℃ Freezer
MSDS:
Inquire
Application:
antidepressant effect
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
QYSYOGCIDRANAR-UHFFFAOYSA-N
InChI:
InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3
Canonical SMILES:
CC1=CC(=NO1)C2=NN=CC3=C(C(=NN32)OCC4=NC=NN4C)C(C)(C)C
Current Developer:
Merck & Co
1.In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
Atack JR1, Maubach KA, Wafford KA, O'Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NG, McKernan RM, Murphy MG, Gingrich K, Dawson G J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. doi: 10.1124/jpet.109.157636. Epub 2009 Aug 24.
3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016) is a pyrazolotriazine with an affinity of between 0.8 and 1.5 nM for the benzodiazepine binding site of native rat brain and recombinant human alpha1-, alpha2-, alpha3-, and alpha5-containing GABA(A) receptors. It has inverse agonist efficacy selective for the alpha5 subtype, and this alpha5 inverse agonism is greater than that of the prototypic alpha5-selective compound 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-hdyl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine (alpha5IA). Consistent with its greater alpha5 inverse agonism, MRK-016 increased long-term potentiation in mouse hippocampal slices to a greater extent than alpha5IA. MRK-016 gave good receptor occupancy after oral dosing in rats, with the dose required to produce 50% occupancy being 0.39 mg/kg and a corresponding rat plasma EC(50) value of 15 ng/ml that was similar to the rhesus monkey plasma EC(50) value of 21 ng/ml obtained using [(11)C]flumazenil positron emission tomography.
2.Administration of the inverse benzodiazepine agonist MRK-016 rescues acquisition and memory consolidation following peripheral administration of bacterial endotoxin.
Eimerbrink MJ1, White JD1, Pendry RJ1, Hodges SL1, Sadler LN1, Wiles JD1, Weintraub MK1, Chumley MJ2, Boehm GW3. Behav Brain Res. 2015 Jul 15;288:50-3. doi: 10.1016/j.bbr.2015.03.048. Epub 2015 Mar 28.
Recent evidence suggests that inflammation-induced decrements in cognitive function can be mitigated via manipulation of excitatory or inhibitory transmission. We tested the ability of the inverse benzodiazepine agonist, MRK-016 (MRK) to protect against LPS-induced deficits in memory acquisition and consolidation, using a contextual fear conditioning (CFC) paradigm. In Experiment One, mice received lipopolysaccharide (LPS) and/or MRK injections prior to CFC training, and were then tested 24h after training. In Experiment Two, animals received similar treatment injections immediately after training, and were tested 24h later. Additionally, hippocampal samples were collected 4h after LPS injections and immediately after testing, to evaluate brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) mRNA expression. Results indicate that MRK can protect against LPS-induced learning/memory decrements in both paradigms.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


RuBi GABA trimethylphosphine

RuBi GABA trimethylphosphine is the modified version of RuBi-GABA, which inhibits neural activity in vivo and is suitable for use as alternative for GABA agonis...

CAS 145645-62-1 NNC 711

NNC 711
(CAS: 145645-62-1)

NNC 711 is a GABA uptake inhibitor by GAT-1 with IC50 values of 0.04, 171, 1700 and 622 μM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1. NNC 711 is an anticonvulsantag...

CAS 951650-22-9 NS 11394

NS 11394
(CAS: 951650-22-9)

NS 11394 is a drug with selectivity for the α3 and α5 subtypes. It acts as a subtype-selective positive allosteric modulator at GABAA receptors. It is used as a...

CAS 184845-18-9 NNC 05-2090 hydrochloride

NNC 05-2090 hydrochloride
(CAS: 184845-18-9)

NNC052090 is a GABA uptake inhibitor that displays selectivity for BGT-1 (mGAT-2) transporters.

CAS 38090-53-8 TACA

TACA
(CAS: 38090-53-8)

TACA, the trans-isomer of CACA, is a potent GABAA and GABAC agonist, GABA uptake inhibitor and substrate for GABA-T. It also acts as a GABAA-ρ agonist.

CAS 77337-73-6 Acamprosate calcium

Acamprosate calcium
(CAS: 77337-73-6)

Acamprosate calcium is a gamma-aminobutyric acid(GABA)agonist and modulator of glutamatergic systems. It has been used in alcohol dependence treatments and may ...

CAS 57717-80-3 CGP7930

CGP7930
(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 371962-01-5 ZAPA sulfate

ZAPA sulfate
(CAS: 371962-01-5)

ZAPA sulfate acts as an agonist at low affinity GABAA receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. ZA...

Chemical Structure

CAS 783331-24-8 MRK 016

Quick Inquiry

Verification code

Featured Items